PULMATRIX
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.
PULMATRIX
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.pulmatrix.com
Total Employee:
11+
Status:
Active
Contact:
(781)357-2399
Email Addresses:
[email protected]
Total Funding:
148.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Font Awesome Apache Microsoft Exchange Online Office 365 Mail IPv6
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Mapp Biopharmaceutical
Mapp Biopharmaceutical was created to develop novel pharmaceuticals for the prevention and treatment of infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
National Heart, Lung and Blood Institute
National Heart, Lung and Blood Institute investment in Grant - Pulmatrix
Polaris Partners
Polaris Partners investment in Post-IPO Equity - Pulmatrix
ARCH Venture Partners
ARCH Venture Partners investment in Post-IPO Equity - Pulmatrix
Altitude Life Science Ventures
Altitude Life Science Ventures investment in Post-IPO Equity - Pulmatrix
5AM Ventures
5AM Ventures investment in Post-IPO Equity - Pulmatrix
Polaris Partners
Polaris Partners investment in Series B - Pulmatrix
5AM Ventures
5AM Ventures investment in Series B - Pulmatrix
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Pulmatrix
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Pulmatrix
5AM Ventures
5AM Ventures investment in Series B - Pulmatrix
Official Site Inspections
http://www.pulmatrix.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.63 K
- Host name: 209.114.180.107.host.secureserver.net
- IP address: 107.180.114.209
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Pulmatrix"
Pulmatrix Inc. - LinkedIn
PULMATRIX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally ...See details»
PULMATRIX, INC. - Crunchbase Company Profile
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease …See details»
Pulmatrix, Inc. - AnnualReports.com
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product …See details»
Pulmatrix Company Profile - Office Locations, Competitors, …
Pulmatrix has 3 employees at their 1 location and $7.3 m in annual revenue in FY 2023. See insights on Pulmatrix including office locations, competitors, revenue, financials, executives, …See details»
PULMATRiX
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases and central nervous system (“CNS”) disorders using …See details»
Pulmatrix - News, Mergers and Acquisitions, Locations and …
Pulmatrix is a clinical-stage biopharmaceutical company focused on developing novel inhaled therapeutic products for CNS, respiratory, and other diseases using its patented iSPERSE™ …See details»
Our Story - PULMATRiX
PULMATRiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE ™ technology to optimally deliver both respiratory and …See details»
Pulmatrix Announces First Quarter 2025 Financial …
3 days ago About Pulmatrix, Inc. Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory ...See details»
Pulmatrix - Crunchbase Company Profile & Funding
Mar 21, 2025 PULMATRIX is novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology ... Experience the new Crunchbase, powered by AI . Experience the new Crunchbase, powered …See details»
Pulmatrix, Inc. (PULM): history, ownership, mission, how it works ...
[relinking] Home History Owners Mission How It Works How It Makes Money Pulmatrix, Inc. (PULM) Information A Brief History of Pulmatrix, Inc. (PULM) Company Overview Pulmatrix, …See details»
Pulmatrix Announces First Quarter 2025 Financial Results
4 days ago Pulmatrix's innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable …See details»
PULMATRiX
4 days ago At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our …See details»
Investors - PULMATRiX
Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies.See details»
Pulmatrix Announces First Quarter 2025 Financial Results and …
3 days ago About Pulmatrix, Inc. Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine …See details»
PULMATRIX, INC. - Funding, Financials, Valuation & Investors
PULMATRIX, INC. is registered under the ticker NASDAQ:PULM . Their stock opened with $7.20 in its Mar 28, 2014 IPO. PULMATRIX, INC. is funded by 6 investors. National Heart, Lung and …See details»
Leadership - PULMATRiX
Mr. Kramer is responsible for the Quality function in addition to overseeing the safety and facilities functions at PULMATRIX. Since joining the company in 2009, Mr. Kramer has progressed …See details»
PULMATRiX
Nov 13, 2024 Information about Pulmatrix's directors and executive officers, including a description of their interests in Pulmatrix, is included in Pulmatrix's most recent Annual Report …See details»
PULMATRIX, INC. - Contacts, Employees, Board Members
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases. ... Experience the new Crunchbase, powered by AI . …See details»
Leadership - PULMATRiX
Peter Ludlum Interim Chief Executive Officer. Mr. Ludlum is an experienced financial executive with over 23 years of work with early-stage and high growth companies within the life science …See details»
PULMATRiX
4 days ago FRAMINGHAM, Mass., May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the …See details»